Prometic Biosciences Inc.

Prometic Pharma Smt Limited

Jean-François Bienvenu

Boulos Zacharie

Lyne Gagnon

Brigitte Grouix

Christopher L Penney

Shaun Abbott

Pierre Laurin

Valérie Perron

Lilianne Geerts

François Sarra-Bournet

Jean-Simon Duceppe

Martin Leduc

Daniel Fortin

Nicole Wilb

Abdallah Ezzitouni

Nancie Moreau

Alan D Cameron

Karine Houde

Shaun D Abbott

The present invention relates to substituted aromatic compounds for use in prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis, where the compound has the following formula: or a pharmaceutically acceptable salt thereof, wherein A is Calkyl, Calkyl, Calkenyl, Calkenyl, C(O)&#x2014;(CH)&#x2014;CHor CH(OH)&#x2014;(CH)&#x2014;CHwherein n is 3 or 4; Ris H, OH or F; Ris H, OH, F or CH&#x2014;OH; Ris H, OH, F or CHPh; Ris H, OH or F; Q is 1) (CH)C(O)OH wherein m is 1 or 2, 2) CH(CH)C(O)OH, 3) C(CH)C(O)OH, 4) CH(F)&#x2014;C(O)OH, 5) CF&#x2014;C(O)OH, or 6) C(O)&#x2014;C(O)OH. 

Substituted aromatic compounds for the treatment pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis

Phenylketone carboxylate compounds of Formula I, wherein n=2-6; R&#x2550;C(0); &#x2014;OC(O)&#x2014; or &#x2014;CH(OH)&#x2014;; A is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when B is Ft B is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when A is Ft or A and B form a 5-7 membered cycloalkyl substituted with COOFt W=0, S or NFt Y=0,S,NH or CH2; m=0-2; p=1-7; have been prepared. These compounds and their pharmaceutically acceptable salts have beneficial therapeutic effects to prevent or treat a condition related to (l) blood disorders, (ii) inflammation related diseases, (iii) renal disorders and/or renal disorders complications, or (iv) fibrosis-related organ dysfunction. 

Phenylketone carboxylate compounds and pharmaceutical uses thereof

The present invention relates to substituted aromatic compounds of Formula I and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds in the prevention and/or treatment of various diseases and conditions in subjects, including the prevention or treatment of (i) blood disorders, (ii) renal disorders, a nephropathies, or renal disorder complications; (iii) inflammatory-related diseases; and/or (iv) oxidative stress related disorders.

Substituted aromatic compounds and pharmaceutical uses thereof

Compounds containing two mono- or disubstituted triazine rings covalently linked by an organic linker, but not linked directly to each other, may be used to treat autoimmune diseases. Autoimmune diseases which are amenable to treatment with compounds of this invention include rheumatoid arthritis, systemic lupus erythematosus (SLE), idiopathic (immune) thrombocytopenia (ITP), glomerulonephritis and vasculitis. The present invention also relates to reducing drug toxicity which often accompanies traditional therapies for autoimmune diseases. The compounds may also be used to bind antibody in vitro or ex vivo.

Triazine dimers for the treatment of autoimmune diseases

Growing community of inventors

St-Augustin-de-Mesmaures, Canada

Jean-François Bienvenu